HALO vs. ENVA
HALO (Halozyme Therapeutics, Inc.) and ENVA (Enova International, Inc.) are both stocks. HALO operates in Biotechnology (Healthcare), while ENVA operates in Credit Services (Financial Services). Over the past 10 years, HALO returned 22.84%/yr vs 38.77%/yr for ENVA. At a 0.25 correlation, their price movements are largely independent.
Performance
HALO vs. ENVA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, HALO achieves a 3.27% return, which is significantly lower than ENVA's 20.44% return. Over the past 10 years, HALO has underperformed ENVA with an annualized return of 22.84%, while ENVA has yielded a comparatively higher 38.77% annualized return.
HALO
- 1D
- -1.74%
- 1M
- 0.42%
- YTD
- 3.27%
- 6M
- 11.72%
- 1Y
- 28.75%
- 3Y*
- 27.10%
- 5Y*
- 10.19%
- 10Y*
- 22.84%
ENVA
- 1D
- -0.14%
- 1M
- 13.51%
- YTD
- 20.44%
- 6M
- 16.35%
- 1Y
- 102.88%
- 3Y*
- 53.36%
- 5Y*
- 39.68%
- 10Y*
- 38.77%
HALO vs. ENVA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
HALO Halozyme Therapeutics, Inc. | 3.27% | 40.77% | 29.36% | -35.04% | 41.51% | -5.85% | 140.89% | 21.19% | -27.79% | 105.06% |
ENVA Enova International, Inc. | 20.44% | 63.95% | 73.19% | 44.28% | -6.32% | 65.36% | 2.95% | 23.64% | 28.03% | 21.12% |
Correlation
The correlation between HALO and ENVA is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.22 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.23 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.27 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.25 |
Correlation (All Time) Calculated using the full available price history since Nov 13, 2014 | 0.25 |
Fundamentals
HALO:
$8.54B
ENVA:
$4.99B
HALO:
$2.87
ENVA:
$12.29
HALO:
24.26
ENVA:
15.40
HALO:
2.74
ENVA:
0.83
HALO:
5.61
ENVA:
1.53
HALO:
38.88
ENVA:
3.56
HALO:
$1.51B
ENVA:
$3.28B
HALO:
$1.23B
ENVA:
$1.23B
HALO:
$980.05M
ENVA:
$456.13M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
HALO vs. ENVA — Risk / Return Rank
HALO
ENVA
HALO vs. ENVA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Halozyme Therapeutics, Inc. (HALO) and Enova International, Inc. (ENVA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| HALO | ENVA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.69 | ||
| Sortino ratioReturn per unit of downside risk | -1.79 | ||
| Omega ratioGain probability vs. loss probability | 1.17 | 1.40 | -0.23 |
| Calmar ratioReturn relative to maximum drawdown | 1.14 | 4.04 | -2.90 |
| Martin ratioReturn relative to average drawdown | 2.16 | 10.44 | -8.28 |
Loading charts...
Drawdowns
HALO vs. ENVA - Drawdown Comparison
The maximum HALO drawdown since its inception was -74.26%, smaller than the maximum ENVA drawdown of -84.26%. Use the drawdown chart below to compare losses from any high point for HALO and ENVA.
Loading charts...
Drawdown Indicators
| HALO | ENVA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -74.26% | -84.26% | +10.00% |
Max Drawdown (1Y)Largest decline over 1 year | -24.13% | -24.75% | +0.62% |
Max Drawdown (3Y)Largest decline over 3 years | -33.92% | -37.01% | +3.09% |
Max Drawdown (5Y)Largest decline over 5 years | -49.06% | -42.84% | -6.22% |
Max Drawdown (10Y)Largest decline over 10 years | -49.06% | -77.57% | +28.51% |
Current DrawdownCurrent decline from peak | -14.44% | -0.14% | -14.30% |
Average DrawdownAverage peak-to-trough decline | -31.88% | -31.82% | -0.06% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.73% | 9.57% | +3.16% |
Volatility
HALO vs. ENVA - Volatility Comparison
The current volatility for Halozyme Therapeutics, Inc. (HALO) is 8.94%, while Enova International, Inc. (ENVA) has a volatility of 11.26%. This indicates that HALO experiences smaller price fluctuations and is considered to be less risky than ENVA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| HALO | ENVA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.94% | 11.26% | -2.32% |
Volatility (6M)Calculated over the trailing 6-month period | 24.02% | 28.77% | -4.75% |
Volatility (1Y)Calculated over the trailing 1-year period | 30.20% | 38.58% | -8.38% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 39.42% | 40.33% | -0.91% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 42.88% | 49.25% | -6.37% |
Dividends
HALO vs. ENVA - Dividend Comparison
Neither HALO nor ENVA has paid dividends to shareholders.
Financials
HALO vs. ENVA - Financials Comparison
This section allows you to compare key financial metrics between Halozyme Therapeutics, Inc. and Enova International, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
HALO vs. ENVA - Profitability Comparison
HALO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a gross profit of 297.47M and revenue of 376.71M. Therefore, the gross margin over that period was 79.0%.
ENVA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Enova International, Inc. reported a gross profit of 0.00 and revenue of 875.14M. Therefore, the gross margin over that period was 0.0%.
HALO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported an operating income of 184.52M and revenue of 376.71M, resulting in an operating margin of 49.0%.
ENVA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Enova International, Inc. reported an operating income of 207.11M and revenue of 875.14M, resulting in an operating margin of 23.7%.
HALO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a net income of 150.05M and revenue of 376.71M, resulting in a net margin of 39.8%.
ENVA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Enova International, Inc. reported a net income of 91.10M and revenue of 875.14M, resulting in a net margin of 10.4%.
Frequently Asked Questions
HALO and ENVA have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ENVA has higher volatility (11.26%) compared to HALO (8.94%). In terms of maximum drawdown, HALO dropped -74.26% vs ENVA's -84.26%.
ENVA currently has the higher Sharpe Ratio (2.60 vs 0.91), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for HALO and ENVA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer